Layered double hydroxide (LDH) nanoparticles are developed as highly efficient siRNA carriers Yanheng Wu Advisory Team: A/Prof. Zhi Ping (Gordon) Xu Dr.

Slides:



Advertisements
Similar presentations
SYNTHESIS AND PROPERTIES OF SUPRAMOLECULAR COMPOUNDS ON THE BASE OF LAYERED DOUBLE HYDROXIDES Isupov V.P., Tarasov K.A., Chupakhina L.E., Mitrofanova R.P.,
Advertisements

Abstract Glioblastoma multiforme (GBM) is the most common brain cancer of middle aged Americans. Unfortunately, survival rates are typically less than.
Synthesis of Doped Titanium Dioxide Nanoparticles Nanoparticles have been around for millennia, being produced by various natural phenomena. However, since.
Naagarajan Narayanan Vignesh Muthuvijayan* Department of Biotechnology
5th Asia-Pacific Summit on
Improving solubility and cellular absorption of Paclitaxel with solid lipid nanoparticles and cyclodextrin Jong-Suep Baek, Jae-Woo So, Ji-Sook Hwang, Cheong-Weon.
Gene Therapy (III) “Non-Viral Gene Transfer Methods” Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Synthesis of Barium Titanate Nanoclusters Presented by Marc Landeweer Advisor: Prof. Slamovich.
Gene Therapy (IV) “Strategies and Applications” Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Name of presentation Month 2009 Using layered double hydroxide nanoparticles conjugated with CpG to polarise immune responses from Th2 to Th1 bias Shiyu.
MM Intercalation of Organic Molecules into Layered Double Hydroxide (LDH): Comparison of Simulation with Experiment H. Zhang a,b, Z. P. Xu b, G.
Synthesis and characterization of functional nanocontainers for active corrosion protection 2010 INTERNATIONAL WORKSHOP ON ENVIRONMENT AND ENERGY San Diego,
Chapter 2 Chemical Basis of Life Why study chemistry in an Anatomy and Physiology class ? - body functions depend on cellular functions - cellular functions.
Chapt2student 2-1 Human Anatomy and Physiology I CHAPTER 2 Chemical Basis of Life.
NON-VIRAL GENE THERAPY Amanda Aryee. Gene Therapy Gene therapy is the process of introducing foreign DNA into host cells. Gene therapy has the potential.
Nanotechnology in Medicine Krešimir Pavelić, Marijeta Kralj and Damir Kralj Division of Molecular Medicine and Division of Material Chemistry Ruđer.
Products > B16-F10 Transfection Reagent (Mouse Melanoma Cells) Altogen Biosystems offers the B16-F10 Transfection Reagent among a host of 100+ cell line.
Products > 293T/17 Transfection Reagent (Embryonic Kidney Cells, CRL-11268) Altogen Biosystems offers the 293T/17 Transfection Reagent among a host of.
Products > Transfection Reagent for BMS/BMS2 Cells (Bone Marrow Cells) Altogen Biosystems offers the BMS2 Transfection Reagent among a host of 100+ cell.
Nanoparticles are particles between 1 and 100 nanometers in size. In nanotechnology, a particle is defined as a small object that behaves as a whole unit.
Products > U87 Transfection Reagent (Glioblastoma Cells) Altogen Biosystems offers the U87 Transfection Reagent among a host of 100+ cell line specific.
Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.
Products > 3T3-L1 Transfection Reagent (Embryonic Fibroblast Cells, CL-173) Altogen Biosystems offers the 3T3-L1 Transfection Reagent among a host of 100+
Dr Gillian Hutcheon Reader in Biomaterials School of Pharmacy and Biomolecular Sciences Liverpool John Moores University Polymeric nanoparticles for the.
Products > HUVEC Transfection Reagent (Human Umbilical Vein Endothelial Cells) Altogen Biosystems offers the HUVEC Transfection Reagent among a host of.
Products > HEK-293 Transfection Reagent (Epithelial Kidney Cells) Altogen Biosystems offers the HEK-293 Transfection Reagent among a host of 100+ cell.
Products > A431 Transfection Reagent (Epidermoid Carcinoma Cells, CRL-1555) Altogen Biosystems offers the A431 Transfection Reagent among a host of 100+
Products > T98G Transfection Reagent (Glioblastoma Cells, CRL-1690)
Effect of mixing sequence of citric acid in the synthesis of Zn0. 3Fe2
Products > NCI-H1299 Transfection Reagent (Lung Adenocarcinoma)
Products > CFPEo (HTRpC) Transfection Reagent (Trachea Epithelium)
Products > HT-29 Transfection Reagent (Colorectal Adenocarcinoma)
Products > 4T1 Transfection Reagent (Breast Cancer Cells, CRL-2539)
Student: Nazar Orishchin Mentor: Dr. Jingyi Chen (CHEM)
Products > SK-MEL-28 Transfection Reagent (Melanoma Cells, HTB72)
Products > RD Transfection Kit (Rhabdomyosarcoma, CCL-136)
Biocompatible Nanoparticles
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > BT-20 Transfection Reagent (Breast Carcinoma Cells)
Products > CT26.WT Transfection Reagent (Colon Carcinoma)
Products > PC-12 Transfection Reagent (Rat Pheochromocytoma Cells)
Products > HCS-2 Transfection Reagent (Chondrosarcoma Cells)
Products > AsPC-1 Transfection Reagent (Pancreatic Beta Cells)
Products > 293 Transfection Reagent (Emb Kidney, CRL-1573)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > Keratinocyte Transfection Reagent (Keratinocytes)
Products > MIA PaCa-2 Transfection Reagent (Pancreatic Carcinoma)
Products > Weri-Rb-1 Transfection Reagent (Retinoblastoma Cells)
Products > HCAEC Transfection Reagent (Coronary Artery Endothelial)
Products > A375 Transfection Reagent (Melanoma Cells, CRL-1619)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > Hepa 1-6 Transfection Reagent (Hepatoma Cells)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > NCI-H441 Transfection Reagent (Lung Adenocarcinoma)
Products > IMR-90 Transfection Reagent (Lung IMR-90, CCL186)
Products > ZR-75-1 Transfection Reagent (Breast Carcinoma, CRL1500)
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
Products > MRC-5 Transfection Reagent (Diploid Fibroblast Cells)
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
Products > NCI-H23 Transfection Reagent (Lung Adenocarcinoma)
Products > HCT-116 Transfection Reagent (Colon Carcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
By JERLIN G. Research Scholar, Department of Physics.
Products > LS-174T Transfection Reagent (Colon Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > CLBPEC Transfection Reagent (Neuroblastoma Cells)
Molecular Therapy - Nucleic Acids
Presentation transcript:

Layered double hydroxide (LDH) nanoparticles are developed as highly efficient siRNA carriers Yanheng Wu Advisory Team: A/Prof. Zhi Ping (Gordon) Xu Dr. Wenyi Gu Prof. Chen Chen

Surgery Radiotherapy Chemotherapy Immunotherapy Current therapeutics for cancer

RNAi based cancer therapy Three strategies: shRNA, miRNA, siRNA

Naked siRNA Low blood stability Low membrane permeability Immunogenicity

DrugTargetDelivery system Administration routeDiseasePhaseCompany siRNA-EphA2- DOPC EphA2LNPIntravenous injection Advanced Cancers IM.D. Anderson Cancer Center Atu027PKN3LNPIntravenous injection Advanced Solid Tumors ISilence Therapeutics GmbH TKM PLK1LNPHepatic intra- arterial administration Multiple Cancers INational Cancer Institute (NCI) ALN-VSP02KSP and VEGFLNPIntravenous injection Solid tumorsIAlnylam Pharmaceuticals CALAA-01RRM2Cyclodextrin NPIntravenous injection Cancer Solid Tumor ICalando Pharmaceuticals siG12D LODERKRASLODER polymerIntratumoral administration Pancreatic Ductal Adenocarcinom a Pancreatic Cancer ISilenseed Ltd Xu, C. F., & Wang, J. (2015). Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences, 10(1), Current delivery systems for siRNA drug

[M 2+ (1-x) M 3+ x (OH)]A n- (x/n) ·m H 2 O LDH can protect polar and anionic biomolecules through surface absorbance and anion exchange Layered double hydroxide (LDH) nanoparticles

Drug deliveryAnti-cancer drugs (e.g. doxorubicin, doxifluridine,and 5-fluorouracil) Antiinflammatory drugs (e.g. diclofenac, ibuprofen, and glucuronic acid) Gene deliveryHepatitis B virus DNA vaccine Oligonucleotide, PCR fragment ProteinBovine serum albumin (BSA), Ovalbumin(OVA)

siRNA Cl - H2OH2O High loading capacity High biocompatibility Low cytotoxicity Low cost Mg 2 Al-Cl-LDH nanoparticles for siRNA delivery

LDH nanoparticle endocytosis and cellular trafficking

Task I: Synthesis and characterisation of LDH nanoparticles Task II: Optimisation of siRNA delivery with LDH and siRNA mimicking dsDNA-cy5 -Optimise the mixing style -Optimise the mass ratio of LDH to siRNA -Optimise the incubation time What is the optimal parameters for LDH-siRNA delivery?

Task I: Synthesis of Mg 2 Al-Cl-LDH nanoparticles MgCl 2 AlCl 3 NaOH LDH slurry LDH suspension Step1 Mixed solution containing MgCl 2 and AlCl 3 was quickly added into NaOH solution, under vigorous stirring Step2 After stirring, pure LDH slurry was obtained via centrifuge and wash Step 3 Resuspend LDH with deionised water Step 4 Transfer LDH into autoclave, followed by hydrothermal treatment

Characterisation of Mg 2 Al-CL-LDH Particle size distribution (A),TEM image (B), FTIR spectra (C) and XRD pattern (D) of Mg 2 Al-Cl-LDH nanoparticles in the suspension AB CD

Task II: Optimisation of siRNA delivery with LDH and dsDNA-cy5 CNE2(Nasopharyngeal cancer cell) Different mixing styles Different LDH/dsDNA mass ratios Different incubation time dsDNA-cy5 LDH FACS

Cytotoxicity of LDH nanoparticles to nasopharyngeal cancer cells Even at the concentration of 400µg/ml, LDH did not show cytotoxicity to CNE2 cells

Optimisation of mixing style dsDNA-cy5 LDH Mixing style I

dsDNA-cy5 LDH Optimisation of mixing style Mixing style II

Optimisation of mixing style dsDNA-cy5 LDH Mixing style III

Optimisation of mixing style Mixing style III exhibited the highest uptake efficiency for the siRNA delivery to NPC cells.

The optimal LDH:siRNA mass ratio for siRNA delivery is ranging from 15:1 to 30:1 Optimisation of LDH:siRNA mass ratio

Mass ratio of LDH:dsDNA Trade-off between the loading amount and the carrier dose 15:1 to 30:1 <15:1 >30:1

After four hours, approximately 70% of NPC cells were positive. The dsDNA concentration was 40nM Optimisation of incubation time

Summary LDH nanoparticles are stable inorganic materials with low cytotoxicity. The optimal parameters for LDH-siRNA delivery are: -Mixing style: direct mixing of LDH and siRNA -Mass ratio of LDH:siRNA from 15:1 to 30:1 -Incubation time=4 hours

Acknowledgements Prof. Zhi Ping (Gordon) Xu Dr. Wenyi Gu Prof. Chen Chen All of my colleagues Financial support: UQ International Scholarship